CRSP03 – CRISPR Therapeutics Ltd (CRSP) - Revolutionizing disease treatment through next-generation gene editing technology

Published
Share this article:
banner image

CRSP03 - CRISPR Therapeutics Ltd (CRSP)

CRISPR Therapeutics Ltd (CRSP) is a biotechnology company focused on developing transformative therapies for genetic diseases using CRISPR/Cas9 gene-editing technology.

The company’s research and development efforts span multiple disease areas, utilizing both ex vivo and in vivo gene-editing approaches. CRISPR Therapeutics’ core strengths lie in its strong intellectual property portfolio and deep scientific expertise, which support long-term innovation and the advancement of next-generation therapeutic solutions.

Additional Details

IssuerPi Securities Public Company Limited
DR SymbolCRSP03
DR Reference Ratio500 DR : 1 UL
Underlying SecurityCRISPR Therapeutics Ltd (CRSP)
Type of Underlying SecurityCommon Stock
Exchange of Underlying SecurityU.S. Equities Exchanges
Reference Asset Issuer’s Website CRISPR Website